TerSera Therapeutics
↗Deerfield, IL, USA
TerSera Therapeutics is a privately-held biopharmaceutical company focused on acquiring, developing, and commercializing specialty pharmaceutical products. The company targets therapeutic areas including oncology and rare diseases, aiming to maximize the patient benefit of unique therapeutics through a science-led, patient-centric approach.
Founded in 2016 and backed by the private equity firm GTCR, TerSera has built its portfolio through a series of strategic acquisitions of on-market and development-stage assets. In early 2026, the company announced a strategic move to divest its Infusion Specialty Therapies (IST) business unit to ESTEVE, allowing TerSera to sharpen its focus on its core oncology and rare disease portfolio.
CLASSIFICATION
SIZE & FINANCIALS
Employees:51-200
Founded:2016
Ownership:private
Status:operating
FUNDING
Stage:Private Equity Backed
Investors:GTCR
PIPELINE
Stage:Commercial
Lead Drug Stage:Commercial
Modalities:Small molecule
Active Trials:7
Trial Phases:Phase 2: 1
FDA Approvals:4
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:ESTEVE (Acquirer of IST business unit), MacroGenics (Acquired Margenza rights), Lexicon Pharmaceuticals (Acquired Xermelo rights)
COMPETITION
Position:Niche Player
Competitors:Pfizer, Lexicon Pharmaceuticals
LEADERSHIP
Key Executives:
Edward Donovan - CEO
Ed Fiorentino - Chairman
LINKS
Website:tersera.com
LinkedIn:LinkedIn Profile
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of TerSera Therapeutics and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with TerSera Therapeutics. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.